PITX2 and breast carcinoma: Summarizing the clinical impact of PITX2 DNA methylation in high-risk breast cancer patients, there is evidence that PITX2 DNA methylation may serve as a valuable predictive marker to distinguish between responding and nonresponding patients (Figure 2).